Vepdegestrant FDA Approval: First PROTAC for Breast Cancer
Review the 2026 FDA approval of vepdegestrant (Veppanu), the first PROTAC targeted protein degrader for ESR1-mutated breast cancer, and its clinical data.
Back to Articles
Articles tagged with “esr1-mutation”